| Original language | English (US) |
|---|---|
| Pages (from-to) | 379-380 |
| Number of pages | 2 |
| Journal | Nature Reviews Neurology |
| Volume | 18 |
| Issue number | 7 |
| DOIs |
|
| State | Published - Jul 2022 |
ASJC Scopus subject areas
- Clinical Neurology
- Cellular and Molecular Neuroscience
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Nature Reviews Neurology, Vol. 18, No. 7, 07.2022, p. 379-380.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease
AU - Knopman, David
AU - Sano, Mary
AU - Feldman, Howard H.
N1 - Funding Information: D.K. serves on a Data Safety Monitoring Board (DSMB) for the Dominantly Inherited Alzheimer Network (DIAN) study. He served on a data safety monitoring board for a tau therapeutic for Biogen but received no personal compensation. He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California. He has served as a consultant for Roche, Samus Therapeutics, Magellan Health and Alzeca Biosciences but receives no personal compensation. He receives funding from the NIH. M.S. serves as a consultant for Eisai, Avenir, vTv, Biogen, BioXcel, Hoffman LaRoche, NovoNordisk, Novartis and Merck. She chairs the DSMB for the Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer’s Disease (SESAD), sponsored by the University of Colorado. She receives funding from the NIH. H.H.F. serves as a member of a DSMB/Data Monitoring Committee for Janssen Research and Development and the Roche/Banner Institute, for which he does not receive personal compensation. He receives grant funding through the University of California San Diego (UCSD) from Biohaven Pharmaceuticals, Annovis (QR Pharma), AC Immune, Vivoryon (Probiodrug) and LuMind Foundation and has service agreements for consulting through UCSanD with Novo Nordisk, Samus Therapeutics, Samumed, Tau Consortium & Rainwater Charitable Foundation and Axon Neurosciences, for which he does not receive personal compensation. He holds grant funding from the NIH and the Canadian Institutes of Health Research.
PY - 2022/7
Y1 - 2022/7
UR - http://www.scopus.com/inward/record.url?scp=85130264022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130264022&partnerID=8YFLogxK
U2 - 10.1038/s41582-022-00672-3
DO - 10.1038/s41582-022-00672-3
M3 - Comment/debate
C2 - 35596071
AN - SCOPUS:85130264022
SN - 1759-4758
VL - 18
SP - 379
EP - 380
JO - Nature Reviews Neurology
JF - Nature Reviews Neurology
IS - 7
ER -